JP2020530493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530493A5 JP2020530493A5 JP2020530423A JP2020530423A JP2020530493A5 JP 2020530493 A5 JP2020530493 A5 JP 2020530493A5 JP 2020530423 A JP2020530423 A JP 2020530423A JP 2020530423 A JP2020530423 A JP 2020530423A JP 2020530493 A5 JP2020530493 A5 JP 2020530493A5
- Authority
- JP
- Japan
- Prior art keywords
- bacterial strain
- pharmaceutical composition
- bacterial
- feces
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001580 bacterial effect Effects 0.000 claims description 178
- 239000008194 pharmaceutical composition Substances 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 80
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 55
- 241000894006 Bacteria Species 0.000 claims description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 210000000936 intestine Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002550 fecal effect Effects 0.000 claims description 5
- 210000003608 fece Anatomy 0.000 claims 11
- 150000004666 short chain fatty acids Chemical group 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 241000701474 Alistipes Species 0.000 claims 2
- 241000606125 Bacteroides Species 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 241000186394 Eubacterium Species 0.000 claims 2
- 241001608234 Faecalibacterium Species 0.000 claims 2
- 241000785902 Odoribacter Species 0.000 claims 2
- 241000605947 Roseburia Species 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229940005605 valeric acid Drugs 0.000 claims 1
- 241000607142 Salmonella Species 0.000 description 44
- 241000193403 Clostridium Species 0.000 description 36
- 244000052769 pathogen Species 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 14
- 238000011319 anticancer therapy Methods 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 14
- 241000192142 Proteobacteria Species 0.000 description 12
- 241000589876 Campylobacter Species 0.000 description 8
- 241000194033 Enterococcus Species 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 108090000204 Dipeptidase 1 Proteins 0.000 description 6
- 241000588921 Enterobacteriaceae Species 0.000 description 6
- 241000607768 Shigella Species 0.000 description 6
- 102000006635 beta-lactamase Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 241000606161 Chlamydia Species 0.000 description 4
- 241000305071 Enterobacterales Species 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 4
- 241000589989 Helicobacter Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000186359 Mycobacterium Species 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 241000607598 Vibrio Species 0.000 description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 4
- 229940124307 fluoroquinolone Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 241000607528 Aeromonas hydrophila Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000589968 Borrelia Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- 241000589874 Campylobacter fetus Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000589601 Francisella Species 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241001503405 Leptosira Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000984031 Orientia Species 0.000 description 2
- 241000607000 Plesiomonas Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000607265 Vibrio vulnificus Species 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 208000037815 bloodstream infection Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940098232 yersinia enterocolitica Drugs 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542033P | 2017-08-07 | 2017-08-07 | |
| US62/542,033 | 2017-08-07 | ||
| PCT/US2018/045592 WO2019032572A1 (en) | 2017-08-07 | 2018-08-07 | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530493A JP2020530493A (ja) | 2020-10-22 |
| JP2020530493A5 true JP2020530493A5 (enExample) | 2021-09-24 |
Family
ID=65272652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530423A Pending JP2020530493A (ja) | 2017-08-07 | 2018-08-07 | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200093870A1 (enExample) |
| EP (1) | EP3665181A4 (enExample) |
| JP (1) | JP2020530493A (enExample) |
| KR (1) | KR20200037851A (enExample) |
| CN (1) | CN111328331A (enExample) |
| AU (1) | AU2018313765A1 (enExample) |
| CA (1) | CA3072029A1 (enExample) |
| WO (1) | WO2019032572A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| CN104160014A (zh) | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| CA3072032A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
| WO2019079629A1 (en) * | 2017-10-18 | 2019-04-25 | Ascus Biosciences, Inc. | IMPROVING POULTRY PRODUCTION BY ADMINISTERING A SYNTHETIC BIO-ASSEMBLY OF MICROBES OR PURIFIED STEM THEREFOR |
| EP3773645A4 (en) | 2018-04-10 | 2021-11-24 | Siolta Therapeutics, Inc. | MICROBIAL CONSORTIA |
| WO2020132098A1 (en) * | 2018-12-19 | 2020-06-25 | Healthy Cow Corporation | Ready-to-use probiotic compositions and uses thereof |
| PE20221399A1 (es) | 2019-07-19 | 2022-09-15 | Finch Therapeutics Holdings Llc | Metodos y productos para el tratamiento de trastornos gastrointestinales |
| EP4021467A4 (en) * | 2019-08-28 | 2023-09-13 | Xbiome Inc. | COMPOSITIONS CONTAINING BACTERIAL SPECIES AND ASSOCIATED METHODS |
| US12364721B2 (en) | 2019-09-24 | 2025-07-22 | Prolacta Bioscience, Inc. | Compositions and methods for treatment of inflammatory and immune diseases |
| WO2021071864A1 (en) | 2019-10-07 | 2021-04-15 | Siolta Therapeutics, Inc. | Therapeutic pharmaceutical compositions |
| KR20220101637A (ko) * | 2019-10-18 | 2022-07-19 | 핀치 테라퓨틱스 홀딩스 엘엘씨 | 박테리아 대사산물을 대상체에 전달하기 위한 조성물 및 방법 |
| GB201915144D0 (en) * | 2019-10-18 | 2019-12-04 | Multigerm Uk Entpr Ltd | Method of promoting SCFA production by gut microbiota |
| EP3838281A1 (en) * | 2019-12-20 | 2021-06-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2021231804A2 (en) * | 2020-05-13 | 2021-11-18 | President And Fellows Of Harvard College | Methods and compositions for suppressing inflammation induced by gut microbes |
| GB202007452D0 (en) * | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| WO2022036225A1 (en) | 2020-08-14 | 2022-02-17 | Prolacta Bioscience, Inc. | Human milk oligosaccharide compositions for use with bacteriotherapies |
| WO2022050082A1 (ja) * | 2020-09-01 | 2022-03-10 | 国立大学法人東北大学 | 乳汁中のＩｇＡ抗体含有量の増加剤 |
| WO2022071423A1 (ja) * | 2020-09-30 | 2022-04-07 | 国立研究開発法人国立がん研究センター | ルミノコッカッセ腸内菌投与による免疫チェックポイント阻害薬の抗腫瘍効果の増強 |
| JP2023550652A (ja) * | 2020-11-25 | 2023-12-04 | セレス セラピューティクス インコーポレイテッド | 移植片対宿主病を処置するための設計された細菌組成物 |
| US20230149483A1 (en) * | 2021-11-12 | 2023-05-18 | Iowa State University Research Foundation, Inc. | Short-chain fatty acid use to mitigate antimicrobial resistance and virulence gene transfer in the gut |
| WO2023100989A1 (ja) * | 2021-12-02 | 2023-06-08 | 国立大学法人東北大学 | 下痢治療剤および牛の下痢治療方法 |
| KR102780901B1 (ko) * | 2022-11-09 | 2025-03-17 | 주식회사 굿바이옴텍 | 베타-락탐계 항생제 내성 유전자 ｂｌａＣＴＸ－Ｍ－２２９ 및 퀴놀론계 항생제 내성 유전자 ｑｎｒＳ를 갖는 신규한 다제내성 대장균 균주 및 이의 용도 |
| CN116747227B (zh) * | 2023-08-12 | 2025-07-25 | 杭州市第一人民医院 | 泊马度胺在制备抗细菌感染药物中的应用 |
| WO2025093780A1 (en) * | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | The concept of drugs made with the gut microbiota and its components and the method of their administration to obtain effective therapeutic effects |
| WO2025093778A1 (en) | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727061B2 (en) * | 1997-02-20 | 2004-04-27 | Cabtec, Inc. | Methods for identifying species or Shigella and E. coli using operon sequence analysis |
| ATE393221T1 (de) * | 1999-11-29 | 2008-05-15 | Avi Biopharma Inc | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
| CN103561752B (zh) * | 2011-03-09 | 2016-04-20 | 明尼苏达大学评议会 | 用于移植结肠微生物群的组合物和方法 |
| CN104160014A (zh) * | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| US8921335B2 (en) * | 2012-01-31 | 2014-12-30 | The Regents Of The University Of California | Oral delivery of nucleic acid-based gene interfering agents by Salmonella |
| AU2014232370B2 (en) * | 2013-03-15 | 2018-11-01 | Société des Produits Nestlé S.A. | Network-based microbial compositions and methods |
| AU2014275025B2 (en) * | 2013-06-05 | 2016-12-01 | Ferring Microbiome Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
| CA3072032A1 (en) * | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
-
2018
- 2018-08-07 CN CN201880064759.2A patent/CN111328331A/zh active Pending
- 2018-08-07 KR KR1020207006802A patent/KR20200037851A/ko not_active Ceased
- 2018-08-07 CA CA3072029A patent/CA3072029A1/en active Pending
- 2018-08-07 AU AU2018313765A patent/AU2018313765A1/en not_active Abandoned
- 2018-08-07 EP EP18843326.2A patent/EP3665181A4/en active Pending
- 2018-08-07 JP JP2020530423A patent/JP2020530493A/ja active Pending
- 2018-08-07 WO PCT/US2018/045592 patent/WO2019032572A1/en not_active Ceased
-
2019
- 2019-12-09 US US16/707,277 patent/US20200093870A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,022 patent/US20240307460A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530493A5 (enExample) | ||
| JP2020530494A5 (enExample) | ||
| AU2010339573B2 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| US20210106629A1 (en) | Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders | |
| Trop | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease | |
| JP2009537547A (ja) | 生物学的治療組成物およびその使用 | |
| WO2012142605A1 (en) | Rapid recolonization deployment agent | |
| JP2019525944A (ja) | 潰瘍性大腸炎を治療するための方法 | |
| JP2019502724A (ja) | 腸内細菌叢を調節するための治療 | |
| Qasemi et al. | The power of probiotics to combat urinary tract infections: A comprehensive review | |
| Gionchetti et al. | Probiotics for the treatment of postoperative complications following intestinal surgery | |
| Faubion et al. | Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad | |
| WO2014011233A1 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| Khan et al. | pylori Infection in human Gastrointestinal Cancer Diagnosis and Treatment Control: A review | |
| US11529375B2 (en) | Compositions and methods for treating diverticulitis and related disorders | |
| Fakayode | Correlation Between Reactive Oxygen Species and Synbiotics for Effective | |
| EA050195B1 (ru) | Лечение микробного дисбиоза | |
| Guercini et al. | 97: Long Lasting Therapy for Recurrent Urinary Tract Infections in Women | |
| Gionchetti et al. | Probiotics in IBD: A Critical Review | |
| Burch | Understanding the rationale and use of probiotics in the treatment of IBD | |
| Kroeker et al. | 76 Probiotics in Pouchitis and Ulcerative Colitis | |
| Lima et al. | eBook on Inflammatory Bowel Disease | |
| Calafiore et al. | Gastroenterology and Hepatology Research | |
| Zadravec et al. | Manipulation of Intestinal Flora as a Way to Treat Crohn’s Disease: The Role of Probiotics, Prebiotics and Antibiotics | |
| Darbandi et al. | For personal private use only. |